ErbB/HER protein-tyrosine kinases: Structures and small molecule inhibitors

Pharmacological Research

Volumn 87, Issue , 2014, Pages 42-59

  Roskoski Jr , Robert ^a  

^a Blue Ridge Institute for Medical Research   (United States)

Author keywords

Catalytic spine; EGFR; Gatekeeper residue; Regulatory spine; Targeted cancer therapy; Transition state inhibitor

Indexed keywords

AFATINIB; CANERTINIB; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; ERLOTINIB; GEFITINIB; LAPATINIB; MAGNESIUM ION; NERATINIB; PELITINIB; PROTEIN TYROSINE KINASE; VANDETANIB; VEMURAFENIB; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR;

ARTICLE; BINDING AFFINITY; BINDING SITE; CLINICAL TRIAL (TOPIC); CONFORMATIONAL TRANSITION; DIMERIZATION; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG TARGETING; ENZYME CONFORMATION; ENZYME MECHANISM; ENZYME STRUCTURE; HEAD AND NECK SQUAMOUS CELL CARCINOMA; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROTEIN INTERACTION; PROTEIN SECONDARY STRUCTURE; PROTEIN STRUCTURE; RECEPTOR UPREGULATION; STRUCTURE ANALYSIS; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOCATALYSIS; CHEMISTRY; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; BIOCATALYSIS; ERBB RECEPTORS; HUMANS; PROTEIN CONFORMATION; PROTEIN KINASE INHIBITORS;

EID: 84903581634     PISSN: 10436618     EISSN: 10961186     Source Type: Journal    
DOI: 10.1016/j.phrs.2014.06.001     Document Type: Review

References (116)

1. M.A. Lemmon, and J. Schlessinger Cell signaling by receptor tyrosine kinases Cell 141 2010 1117 1134
2. G. Carpenter, and S. Cohen Epidermal growth factor J Biol Chem 265 1990 7709 7712 (Pubitemid 20158927)
3. R. Roskoski Jr. The ErbB/HER family of protein-tyrosine kinases and cancer Pharmacol Res 79 2014 34 74
4. G. Manning, D.B. Whyte, R. Martinez, T. Hunter, and S. Sudarsanam The protein kinase complement of the human genome Science 298 2002 1912 1934 (Pubitemid 35425239)
5. A. Alonso, J. Sasin, N. Bottini, I. Friedberg, I. Friedberg, and A. Osterman et al. Protein tyrosine phosphatases in the human genome Cell 117 2004 699 711 (Pubitemid 38748887)
6. P. Cohen Protein kinases - the major drug targets of the twenty-first century? Nat Rev Drug Discov 1 2002 309 315 (Pubitemid 37361447)
7. R. Roskoski Jr. ERK1/2 MAP kinases: structure, function, and regulation Pharmacol Res 66 2012 105 143
8. M. Rask-Andersen, S. Masuram, and H.B. Schiöth The druggable genome: evaluation of drug targets in clinical trials suggests major shifts in molecular class and indication Annu Rev Pharmacol Toxicol 54 2014 9 26
9. A.L. Schechter, D.F. Stern, L. Vaidyanathan, S.J. Decker, J.A. Drebin, and M.I. Greene et al. The neu oncogene: an erb-B-related gene encoding a 185,000-Mr tumour antigen Nature 312 1984 513 516 (Pubitemid 15182278)
10. A. Ullrich, L. Coussens, J.S. Hayflick, T.J. Dull, A. Gray, and A.W. Tam et al. Human epidermal growth factor receptor cDNA sequence and aberrant expression of the amplified gene in A431 epidermoid carcinoma cells Nature 309 1984 418 425 (Pubitemid 14102443)
11. R. Ghosh, A. Narasanna, S.E. Wang, S. Liu, A. Chakrabarty, and J.M. Balko et al. Trastuzumab has preferential activity against breast cancers driven by ERBB2 homodimers Cancer Res 71 2011 1871 1882
12. F. Shi, S.E. Telesco, Y. Liu, R. Radhakrishnan, and M.A. Lemmon ErbB3/HER3 intracellular domain is competent to bind ATP and catalyze autophosphorylation Proc Natl Acad Sci USA 107 2010 7692 7697
13. E. Tzahar, H. Waterman, X. Chen, G. Levkowitz, D. Karunagaran, and S. Lavi et al. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor Mol Cell Biol 16 1996 5276 5287 (Pubitemid 26315047)
14. D. Graus-Porta, R.R. Beerli, J.M. Daly, and N.E. Hynes ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling EMBO J 16 1997 1647 1655 (Pubitemid 27151960)
15. R. Pinkas-Kramarski, L. Soussan, H. Waterman, G. Levkowitz, I. Alroy, and L. Klapper et al. Diversification of Neu differentiation factor and epidermal growth factor signaling by combinatorial receptor interactions EMBO J 15 1996 2452 2467 (Pubitemid 26151185)
16. J. Schlessinger, and Ligand-induced receptor-mediated dimerization and activation of EGF receptor Cell 110 2002 669 672 (Pubitemid 35283957)
17. H. Ogiso, R. Ishitani, O. Nureki, S. Fukai, M. Yamanaka, and J.H. Kim et al. Crystal structure of the complex of human epidermal growth factor and receptor extracellular domains Cell 110 2002 775 787 (Pubitemid 35291060)
18. T.P. Garrett, N.M. McKern, M. Lou, T.C. Elleman, T.E. Adams, and G.O. Lovrecz et al. Crystal structure of a truncated epidermal growth factor receptor extracellular domain bound to transforming growth factor α Cell 110 2002 763 773 (Pubitemid 35283965)
19. A. Arkhipov, Y. Shan, R. Das, N.F. Endres, M.P. Eastwood, and D.E. Wemmer et al. Architecture and membrane interactions of the EGF receptor Cell 152 2013 557 569
20. A.W. Burgess, H.S. Cho, C. Eigenbrot, K.M. Ferguson, T.P. Garrett, and D.J. Leahy et al. An open-and-shut case? Recent insights into the activation of EGF/ErbB receptors Mol Cell 12 2003 541 552 (Pubitemid 37222478)
21. B. Nolen, S. Taylor, and G. Ghosh Regulation of protein kinases; controlling activity through activation segment conformation Mol Cell 15 2004 661 675 (Pubitemid 39194898)
22. J.S. Biscardi, M.C. Maa, D.A. Tice, M.E. Cox, T.H. Leu, and S.J. Parsons c-Src-mediated phosphorylation of the epidermal growth factor receptor on Tyr845 and Tyr1101 is associated with modulation of receptor function J Biol Chem 274 1999 8335 8343
23. N. Gotoh, A. Tojo, M. Hino, Y. Yazaki, and M. Shibuya A highly conserved tyrosine residue at codon 845 within the kinase domain is not required for the transforming activity of human epidermal growth factor receptor Biochem Biophys Res Commun 186 1992 768 774
24. X. Zhang, J. Gureasko, K. Shen, P.A. Cole, and J. Kuriyan An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor Cell 125 2006 1137 1149 (Pubitemid 43866200)
25. L. Jin, W. Wang, and G. Fang Targeting protein-protein interaction by small molecules Annu Rev Pharmacol Toxicol 54 2014 435 456
26. R. Roskoski Jr. RAF protein-serine/threonine kinases: structure and regulation Biochem Biophys Res Commun 399 2010 313 317
27. G. Hatzivassiliou, K. Song, I. Yen, B.J. Brandhuber, D.J. Anderson, and R. Alvarado et al. RAF inhibitors prime wild-type RAF to activate the MAPK pathway and enhance growth Nature 464 2010 431 435
28. D.R. Knighton, J.H. Zheng, L.F. Ten Eyck, V.A. Ashford, N.H. Xuong, and S.S. Taylor et al. Crystal structure of the catalytic subunit of cyclic adenosine monophosphate-dependent protein kinase Science 253 1991 407 414 (Pubitemid 21917165)
29. M.A. Seeliger, P. Ranjitkar, C. Kasap, Y. Shan, D.E. Shaw, and N.P. Shah et al. Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations Cancer Res 69 2009 2384 2392
30. S.S. Taylor, E. Radzio-Andzelm, and T. Hunter How do protein kinases discriminate between serine/threonine and tyrosine? Structural insights from the insulin receptor protein-tyrosine kinase FASEB J 9 1995 1255 1266
31. A.P. Kornev, N.M. Haste, S.S. Taylor, and L.F. Eyck Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism Proc Natl Acad Sci USA 103 2006 17783 17788 (Pubitemid 44852237)
32. D.A. Tice, J.S. Biscardi, A.L. Nickles, and S.J. Parsons Mechanism of biological synergy between cellular Src and epidermal growth factor receptor Proc Natl Acad Sci USA 96 1999 1415 1420 (Pubitemid 29098465)
33. S.S. Taylor, M.M. Keshwani, J.M. Steichen, and A.P. Kornev Evolution of the eukaryotic protein kinases as dynamic molecular switches Philos Trans R Soc Lond B: Biol Sci 367 2012 2517 2528
34. S.S. Taylor, and A.P. Kornev Protein kinases: evolution of dynamic regulatory proteins Trends Biochem Sci 36 2011 65 77
35. K. Aertgeerts, R. Skene, J. Yano, B.C. Sang, H. Zou, and G. Snell et al. Structural analysis of the mechanism of inhibition and allosteric activation of the kinase domain of HER2 protein J Biol Chem 286 2011 18756 18765
36. H.S. Meharena, P. Chang, M.M. Keshwani, K. Oruganty, A.K. Nene, and N. Kannan et al. Deciphering the structural basis of eukaryotic protein kinase regulation PLoS Biol 11 10 2013 e1001680
37. K. Shah, Y. Liu, C. Deirmengian, and K.M. Shokat Engineering unnatural nucleotide specificity for Rous sarcoma virus tyrosine kinase to uniquely label its direct substrates Proc Natl Acad Sci USA 94 1997 3565 3570 (Pubitemid 27180412)
38. Y. Liu, K. Shah, F. Yang, L. Witucki, and K.M. Shokat A molecular gate which controls unnatural ATP analogue recognition by the tyrosine kinase v-Src Bioorg Med Chem 6 1998 1219 1226 (Pubitemid 28398957)
39. R.D. Cauthron, M.M. Symcox, and H. Shuntoh Autoactivation of catalytic (Cα) subunit of cyclic AMP-dependent protein kinase by phosphorylation of threonine 197 Mol Cell Biol 13 1993 2332 2341 (Pubitemid 23097712)
40. J.M. Steichen, M. Kuchinskas, M.M. Keshwani, J. Yang, J.A. Adams, and S.S. Taylor Structural basis for the regulation of protein kinase A by activation loop phosphorylation J Biol Chem 287 2012 14672 14680
41. D.A. Johnson, P. Akamine, E. Radzio-Andzelm, M. Madhusudan, and S.S. Taylor Dynamics of cAMP-dependent protein kinase Chem Rev 101 2001 2243 2270 (Pubitemid 35373018)
42. S.K. Hanks, A.M. Quinn, and T. Hunter The protein kinase family: conserved features and deduced phylogeny of the catalytic domains Science 241 1988 42 52
43. Z. Songyang, K.L. Carraway III, M.J. Eck, S.C. Harrison, R.A. Feldman, and M. Mohammadi et al. Catalytic specificity of protein-tyrosine kinases is critical for selective signalling Nature 373 1995 536 539
44. J. Zhou, and J.A. Adams Participation of ADP dissociation in the rate-determining step in cAMP-dependent protein kinase Biochemistry 36 1997 15733 15738 (Pubitemid 28027372)
45. J. Yang, J. Wu, J.M. Steichen, A.P. Kornev, M.S. Deal, and S. Li et al. A conserved Glu-Arg salt bridge connects coevolved motifs that define the eukaryotic protein kinase fold J Mol Biol 415 2012 666 679
46. A.C. Hengge Mechanistic studies on enzyme-catalyzed phosphoryl transfer Adv Phys Org Chem 40 2005 49 108
47. M. Ho, H.N. Bramson, D.E. Hansen, J.R. Knowles, and E.T. Kaiser Stereochemical course of the phospho group transfer catalyzed by cAMP-dependent protein kinase J Am Chem Soc 110 1988 2680 2681
48. R.D. Guthrie, and W.P. Jencks IUPAC recommendations for the representation of reaction mechanisms Acc Chem Res 10 1989 343 349
49. V.L. Schramm Enzymatic transition states and transition state analog design Annu Rev Biochem 67 1998 693 720 (Pubitemid 28411142)
50. V.L. Schramm Transition states, analogues, and drug development ACS Chem Biol 8 2013 71 81
51. M. Valiev, J. Yang, J.A. Adams, S.S. Taylor, and J.H. Weare Phosphorylation reaction in cAPK protein kinase-free energy quantum mechanical/molecular mechanics simulations J Phys Chem 111 2007 13455 13464 [Erratum in: J Phys Chem 2010;114:6763] (Pubitemid 350241477)
52. Y. Cheng, Y. Zhang, and J.A. McCammon How does the cAMP-dependent protein kinase catalyze the phosphorylation reaction: an ab initio QM/MM study J Am Chem Soc 127 2005 1553 1562 (Pubitemid 40204531)
53. Z.Q. Bao, D.M. Jacobsen, and M.A. Young Briefly bound to activate: transient binding of a second catalytic magnesium activates the structure and dynamics of CDK2 kinase for catalysis Structure 19 2011 675 690
54. L. Pauling Chemical achievement and hope for the future Am Sci 36 1948 51 58
55. T.L. Amyes, and J.P. Richard Specificity in transition state binding: the Pauling model revisited Biochemistry 52 2013 2021 2035
56. E. De Clercq Strategies in the design of antiviral drugs Nat Rev Drug Discov 1 2002 13 25 (Pubitemid 37361400)
57. N.A. Roberts, J.A. Martin, D. Kinchington, A.V. Broadhurst, J.C. Craig, and I.B. Duncan et al. Rational design of peptide-based HIV proteinase inhibitors Science 248 1990 358 361
58. E. De Clercq Antivirals: past, present and future Biochem Pharmacol 85 2013 727 744
59. R.N. Armstrong, H. Kondo, J. Granot, E.T. Kaiser, and A.S. Mildvan Magnetic resonance and kinetic studies of the manganese(II) ion and substrate complexes of the catalytic subunit of adenosine 3′,5′-monophosphate dependent protein kinase from bovine heart Biochemistry 18 1979 1230 1238
60. P.F. Cook, M.E. Neville Jr., K.E. Vrana, F.T. Hartl, and R. Roskoski Jr. Adenosine cyclic 3′,5′-monophosphate dependent protein kinase: kinetic mechanism for the bovine skeletal muscle catalytic subunit Biochemistry 21 1982 5794 5799
61. D.M. Jacobsen, Z.Q. Bao, P. O'Brien, C.L. Brooks 3rd, and M.A. Young Price to be paid for two-metal catalysis: magnesium ions that accelerate chemistry unavoidably limit product release from a protein kinase J Am Chem Soc 134 2012 15357 15370
62. M. Liu, E. Girma, M.A. Glicksman, and R.L. Stein Kinetic mechanistic studies of Cdk5/p25-catalyzed H1P phosphorylation: metal effect and solvent kinetic isotope effect Biochemistry 49 2010 4921 4929
63. W.F. Waas, and K.N. Dalby Physiological concentrations of divalent magnesium ion activate the serine/threonine specific protein kinase ERK2 Biochemistry 42 2003 2960 2970 (Pubitemid 36331540)
64. G. Sun, and R.J. Budde Requirement for an additional divalent metal cation to activate protein tyrosine kinases Biochemistry 36 1997 2139 2146 (Pubitemid 27104705)
65. P.P. Vicario, R. Saperstein, and A. Bennun Role of divalent metals in the kinetic mechanism of insulin receptor tyrosine kinase Arch Biochem Biophys 261 1988 336 345 (Pubitemid 18078290)
66. C. Wang, T.J. Hirai, and J.A. Adams A second magnesium ion is critical for ATP binding in the kinase domain of the oncoprotein v-Fps Biochemistry 37 1998 12624 12630 (Pubitemid 28427547)
67. A. Fersht Enzyme structure and mechanism 2nd ed. 1985 W.H. Freeman and Company New York 105 106
68. 2+-independent neurexin kinase Cell 133 2008 328 339 (Pubitemid 351508303)
69. O. Gerlits, A. Das, M.M. Keshwani, S. Taylor, M.J. Waltman, and P. Langan et al. Metal-free cAMP-dependent protein kinase can catalyze phosphoryl transfer Biochemistry 53 2014 3179 3186
70. J. Zheng, D.R. Knighton, L.F. ten Eyck, R. Karlsson, N. Xuong, and S.S. Taylor et al. Crystal structure of the catalytic subunit of cAMP-dependent protein kinase complexed with MgATP and peptide inhibitor Biochemistry 32 1993 2154 2161 (Pubitemid 23094874)
71. J.A. Adams, and S.S. Taylor Divalent metal ions influence catalysis and active-site accessibility in the cAMP-dependent protein kinase Protein Sci 2 1993 2177 2186 (Pubitemid 23354720)
72. J.A. Adams Kinetic and catalytic mechanisms of protein kinases Chem Rev 101 2001 2271 2290 (Pubitemid 35373019)
73. A.C. Bastidas, M.S. Deal, J.M. Steichen, Y. Guo, J. Wu, and S.S. Taylor Phosphoryl transfer by protein kinase A is captured in a crystal lattice J Am Chem Soc 135 2013 4788 4798
74. Y.H. Peng, H.Y. Shiao, C.H. Tu, P.M. Liu, J.T. Hsu, and P.K. Amancha et al. Protein kinase inhibitor design by targeting the Asp-Phe-Gly (DFG) motif: the role of the DFG motif in the design of epidermal growth factor receptor inhibitors J Med Chem 56 2013 3889 3903
75. R.S. Herbst, J.V. Heymach, and S.M. Lippman Lung cancer N Engl J Med 359 2008 1367 1380
76. T.J. Lynch, D.W. Bell, R. Sordella, S. Gurubhagavatula, R.A. Okimoto, and B.W. Brannigan et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib N Engl J Med 350 2004 2129 2139 (Pubitemid 38637993)
77. J.G. Paez, P.A. Jänne, J.C. Lee, S. Tracy, H. Greulich, and S. Gabriel et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy Science 304 2004 1497 1500 (Pubitemid 38720929)
78. W. Pao, V. Miller, M. Zakowski, J. Doherty, K. Politi, and I. Sarkaria et al. EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib Proc Natl Acad Sci USA 101 2004 13306 13311 (Pubitemid 39209661)
79. E. Massarelli, F.M. Johnson, H.S. Erickson, I.I. Wistuba, and V. Papadimitrakopoulou Uncommon epidermal growth factor receptor mutations in non-small cell lung cancer and their mechanisms of EGFR tyrosine kinase inhibitors sensitivity and resistance Lung Cancer 80 2013 235 241
80. M.H. Cohen, G.A. Williams, R. Sridhara, G. Chen, W.D. McGuinn Jr., and D. Morse et al. United States Food and Drug Administration Drug Approval summary: Gefitinib (ZD1839; Iressa) tablets Clin Cancer Res 10 2004 1212 1218 (Pubitemid 38365209)
81. M.H. Cohen, J.R. Johnson, Y.F. Chen, R. Sridhara, and R. Pazdur FDA drug approval summary: erlotinib (Tarceva) tablets Oncologist 10 2005 461 466 (Pubitemid 41266326)
82. C.H. Yun, T.J. Boggon, Y. Li, M.S. Woo, H. Greulich, and M. Meyerson et al. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity Cancer Cell 11 2007 217 227 (Pubitemid 46349842)
83. M. Red Brewer, C.H. Yun, D. Lai, M.A. Lemmon, M.J. Eck, and W. Pao Mechanism for activation of mutated epidermal growth factor receptors in lung cancer Proc Natl Acad Sci USA 110 2013 E3595 E3604 [Erratum in: Proc Natl Acad Sci USA 2013;110(50):20344]
84. Q. Ryan, A. Ibrahim, M.H. Cohen, J. Johnson, C.W. Ko, and R. Sridhara et al. FDA drug approval summary: lapatinib in combination with capecitabine for previously treated metastatic breast cancer that overexpresses HER-2 Oncologist 13 2008 1114 1119
85. L. Paz-Ares, D. Soulières, I. Melezínek, J. Moecks, L. Keil, and T. Mok et al. Clinical outcomes in non-small-cell lung cancer patients with EGFR mutations: pooled analysis J Cell Mol Med 14 2010 51 69
86. L.V. Sequist, B.A. Waltman, D. Dias-Santagata, S. Digumarthy, A.B. Turke, and P. Fidias et al. Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors Sci Transl Med 3 2011 75ra26
87. F. Solca, G. Dahl, A. Zoephel, G. Bader, M. Sanderson, and C. Klein et al. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker J Pharmacol Exp Ther 343 2012 342 350
88. C.H. Yun, K.E. Mengwasser, A.V. Toms, M.S. Woo, H. Greulich, and K.K. Wong et al. The T790 M mutation in EGFR kinase causes drug resistance by increasing the affinity for ATP Proc Natl Acad Sci USA 105 2008 2070 2075 (Pubitemid 351439466)
89. R. Roskoski Jr. Anaplastic lymphoma kinase (ALK): structure, oncogenic activation, and pharmacological inhibition Pharmacol Res 68 2013 68 94
90. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, and J.O. Park et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043 (Pubitemid 46799492)
91. C. Carmi, M. Mor, P.G. Petronini, and R.R. Alfieri Clinical perspectives for irreversible tyrosine kinase inhibitors in cancer Biochem Pharmacol 84 2012 1388 1399
92. R. Roskoski Jr. The preclinical profile of crizotinib for the treatment of non-small-cell lung cancer and other neoplastic disorders Expert Opin Drug Discov 8 2013 1165 1179
93. R.T. Dungo, and G.M. Keating Afatinib: first global approval Drugs 73 2013 1503 1515
94. V.D. Cataldo, D.L. Gibbons, R. Pérez-Soler, and A. Quintás-Cardama Treatment of non-small-cell lung cancer with erlotinib or gefitinib N Engl J Med 364 2011 947 955
95. C.E. Geyer, J. Forster, D. Lindquist, S. Chan, C.G. Romieu, and T. Pienkowski et al. Lapatinib plus capecitabine for HER2-positive advanced breast cancer N Engl J Med 355 2006 2733 2743 [Erratum in: N Engl J Med 2007;356:1487] (Pubitemid 46021510)
96. R. Riemsma, C.A. Forbes, M.M. Amonkar, K. Lykopoulos, J.R. Diaz, and J. Kleijnen et al. Systematic review of lapatinib in combination with letrozole compared with other first-line treatments for hormone receptor positive (HR+) and HER2+ advanced or metastatic breast cancer (MBC) Curr Med Res Opin 28 2012 1263 1279
97. J.C. Soria, J. Cortes, C. Massard, J.P. Armand, D. De Andreis, and S. Ropert et al. Phase I safety, pharmacokinetic and pharmacodynamic trial of BMS-599626 (AC480), an oral pan-HER receptor tyrosine kinase inhibitor, in patients with advanced solid tumors Ann Oncol 23 2012 463 471
98. M. Majem, and C. Pallarès An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents Clin Transl Oncol 15 2013 343 357
99. 14C] dacomitinib (PF-00299804) in healthy male volunteers Cancer Chemother Pharmacol 72 2013 379 385
100. H.A. Yu, and G.J. Riely Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in lung cancers J Natl Compr Cancer Netw 11 2013 161 169
101. J.T. Jørgensen Role of human epidermal growth factor receptor 2 in gastric cancer: biological and pharmacological aspects World J Gastroenterol 20 2014 4526 4535
102. K. Dorsey, and M. Agulnik Promising new molecular targeted therapies in head and neck cancer Drugs 73 2013 315 325
103. G. Yang, Y. Yao, J. Zhou, and Q. Zhao Effects of icotinib, a novel epidermal growth factor receptor tyrosine kinase inhibitor, in EGFR-mutated non-small cell lung cancer Oncol Rep 27 2012 2066 2072
104. R.B. Cohen Current challenges and clinical investigations of epidermal growth factor receptor (EGFR)- and ErbB family-targeted agents in the treatment of head and neck squamous cell carcinoma (HNSCC) Cancer Treat Rev 2013 S0305-7372(13)00206-5
105. Q. Zhao, J. Shentu, N. Xu, J. Zhou, G. Yang, and Y. Yao et al. Phase I study of icotinib hydrochloride (BPI-2009H), an oral EGFR tyrosine kinase inhibitor, in patients with advanced NSCLC and other solid tumors Lung Cancer 73 2011 195 202
106. W. Liang, X. Wu, W. Fang, Y. Zhao, Y. Yang, and Z. Hu et al. Network meta-analysis of erlotinib, gefitinib, afatinib and icotinib in patients with advanced non-small-cell lung cancer harboring EGFR mutations PLoS ONE 9 2014 e5 8524
107. M. Martin, M. Martin, C.E. Geyer Jr., Y. Ito, J. Ro, and I. Lang et al. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer Eur J Cancer 49 2013 3763 3772
108. L. Gandhi, R. Bahleda, S.M. Tolaney, E.L. Kwak, J.M. Cleary, and S.S. Pandya et al. Phase I study of neratinib in combination with temsirolimus in patients with human epidermal growth factor receptor 2-dependent and other solid tumors J Clin Oncol 32 2014 68 75
109. H.J. Kim, H.P. Kim, Y.K. Yoon, M.S. Kim, G.S. Lee, and S.W. Han et al. Antitumor activity of HM781-36B, a pan-HER tyrosine kinase inhibitor, in HER2-amplified breast cancer cells Anticancer Drugs 23 2012 288 297
110. M.Y. Cha, K.O. Lee, M. Kim, J.Y. Song, K.H. Lee, and J. Park et al. Antitumor activity of HM781-36B, a highly effective pan-HER inhibitor in erlotinib-resistant NSCLC and other EGFR-dependent cancer models Int J Cancer 130 2012 2445 2454
111. H.J. Nam, H.P. Kim, Y.K. Yoon, H.S. Hur, S.H. Song, and M.S. Kim et al. Antitumor activity of HM781-36B, an irreversible Pan-HER inhibitor, alone or in combination with cytotoxic chemotherapeutic agents in gastric cancer Cancer Lett 302 2011 155 165
112. T. Doi, H. Takiuchi, A. Ohtsu, N. Fuse, M. Goto, and M. Yoshida et al. Phase I first-in-human study of TAK-285, a novel investigational dual HER2/EGFR inhibitor, in cancer patients Br J Cancer 106 2012 666 672
113. P. Lorusso, K. Venkatakrishnan, E.G. Chiorean, D. Noe, J.T. Wu, and S. Sankoh et al. Phase 1 dose-escalation, pharmacokinetic, and cerebrospinal fluid distribution study of TAK-285, an investigational inhibitor of EGFR and HER2 Invest New Drugs 32 2014 160 170
114. M.W. Sim, and M.S. Cohen The discovery and development of vandetanib for the treatment of thyroid cancer Expert Opin Drug Discov 9 2014 105 114
115. Y. Sakuma, Y. Yamazaki, Y. Nakamura, M. Yoshihara, S. Matsukuma, and H. Nakayama et al. WZ4002, a third-generation EGFR inhibitor, can overcome anoikis resistance in EGFR-mutant lung adenocarcinomas more efficiently than Src inhibitors Lab Invest 92 2012 371 383
116. M. Sánchez-Martín, and A. Pandiella Differential action of small molecule HER kinase inhibitors on receptor heterodimerization: therapeutic implications Int J Cancer 131 2012 244 252